Journal Article (Editorial)

DZNE-2020-04463

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png B21 Characterisation Of Mice Overexpressing Mutant Huntingtin Lacking The Spine Morphogenesis Regulator Kalirin-7

Ernst, A. (First author)DZNE* ; Schlattmann, P. ; Waldfahrer, F. ; Westhofen, M.

2017
BMJ Publishing Group London

This record in other databases:    

Please use a persistent id in citations: doi:10.1136/jnnp-2014-309032.49

Abstract: The BEMED study (BMJ 2016; 352: DOI 10.1136) was designed as multi-centric, double-blind, plaebo-controlled study in patients with Menière's disease. It should compare a low-level (2 × 24 mg/d) vs. high-level (3 × 48 mg/d) betahstine intake vs. placebo. The primary endpoint was the 'number of vertigo attacks lasting longer than 20 min as documented in a patient's diary'. The main finding of the study was that betahistine did not significantly better reduced the number of vertigo attacks than placebo. Therefore, the BEMED study should be critically discussed in the present paper.

Keyword(s): Adolescent (MeSH) ; Adult (MeSH) ; Aged (MeSH) ; Aged, 80 and over (MeSH) ; Betahistine: therapeutic use (MeSH) ; Dose-Response Relationship, Drug (MeSH) ; Double-Blind Method (MeSH) ; Female (MeSH) ; Germany (MeSH) ; Humans (MeSH) ; Male (MeSH) ; Meniere Disease: classification (MeSH) ; Meniere Disease: diagnosis (MeSH) ; Meniere Disease: drug therapy (MeSH) ; Middle Aged (MeSH) ; Young Adult (MeSH) ; Betahistine

---

Contributing Institute(s):

1. AG N.N. (AG N.N. 3)

Research Program(s):

1. 344 - Clinical and Health Care Research (POF3-344) (POF3-344)

Appears in the scientific report 2017

---

Database coverage:
; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Ebsco Academic Search ; IF >= 10 ; JCR ; National-Konsortium ; SCOPUS ; Web of Science Core Collection

---